Raymond James Financial Services Advisors’s CervoMed CRVO Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-273	Closed	-$5K	–	3295
2022 Q1	$5K	Buy	+273	New	+$5.42K	﹤0.01%	3309
2021 Q4	–	Sell	-1,333	Closed	-$51K	–	3338
2021 Q3	$51K	Hold	1,333	–	–	﹤0.01%	3188
2021 Q2	$73K	Sell	1,333 -1	-0.1%	-$55	﹤0.01%	3179
2021 Q1	$92K	Buy	1,334 +801	+150%	+$67.2K	﹤0.01%	3052
2020 Q4	$32K	Hold	533	–	–	﹤0.01%	2931
2020 Q3	$34K	Buy	+533	New	+$40.5K	﹤0.01%	2793

Other funds holding CRVO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Trexquant Investment Stamford, Connecticut $13.9B AUM 31.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Raymond James Financial Services Advisors's CRVO Position: Q2 2022 in Review

Raymond James Financial Services Advisors sold out of CervoMed (CRVO) in Q2 2022, closing a stake of 273 shares — an estimated $5K sold.

Raymond James Financial Services Advisors first reported a position in CRVO in Q3 2020 and held it in 6 quarters. The position peaked at $92K in Q1 2021. 15 funds tracked by Wall St. Rank hold CRVO as of Q2 2022.

Raymond James Financial Services Advisors reported no remaining CervoMed position as of Q2 2022 after selling out during the quarter.
Raymond James Financial Services Advisors sold 273 CervoMed shares in Q2 2022, an estimated $5K.
Raymond James Financial Services Advisors first reported a position in CervoMed in Q3 2020 and held it in 6 quarters.
Raymond James Financial Services Advisors's CervoMed position peaked at $92K in Q1 2021.
15 funds tracked by Wall St. Rank held CervoMed as of Q2 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.